000 01365 a2200397 4500
005 20250516001926.0
264 0 _c20110315
008 201103s 0 0 eng d
022 _a0008-543X
024 7 _a10.1002/cncr.25489
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aPieters, Rob
245 0 0 _aL-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.
_h[electronic resource]
260 _bCancer
_cJan 2011
300 _a238-49 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
650 0 4 _aAsparaginase
_xadverse effects
650 0 4 _aDrug Combinations
650 0 4 _aDrug Hypersensitivity
650 0 4 _aDrug Monitoring
650 0 4 _aErwinia
_xenzymology
650 0 4 _aHumans
650 0 4 _aPrecursor Cell Lymphoblastic Leukemia-Lymphoma
_xdrug therapy
650 0 4 _aSpironolactone
650 0 4 _aSulfonamides
700 1 _aHunger, Stephen P
700 1 _aBoos, Joachim
700 1 _aRizzari, Carmelo
700 1 _aSilverman, Lewis
700 1 _aBaruchel, Andre
700 1 _aGoekbuget, Nicola
700 1 _aSchrappe, Martin
700 1 _aPui, Ching-Hon
773 0 _tCancer
_gvol. 117
_gno. 2
_gp. 238-49
856 4 0 _uhttps://doi.org/10.1002/cncr.25489
_zAvailable from publisher's website
999 _c20157122
_d20157122